Loss Drugs

• Shoptalk Europe unveiled five major predictions for the future of European retail during its 2026 event in Barcelona. • The forecast identifies AI shopping agents, the rise of weight-loss drugs, a "recommerce boom," personalized physical stores, and revamped supply chain planning as primary drivers of change. • These trends are expected to fundamentally reshape the retail industry over the next decade, impacting how consumers shop and how businesses operate.

Price of dairy product has risen fivefold after users of GLP-1 medications advised to increase protein consumptionThe growing popularity of weight-loss drugs has fuelled global demand for whey protein, sparking concerns among industry experts over a potential shortage.The price of whey has risen fivefold to record levels as companies race to secure supplies amid a boom driven by growing use of GLP-1 drugs, such as Mounjaro, which often require higher protein intake to preserve muscle mass. Continue reading...

Patients with knee arthritis who took medications for at least three years at reduced risk of needing surgeryTaking weight-loss drugs for at least three years could prevent thousands of knee replacements a year, research suggests.Globally, more than 500 million people have osteoarthritis. Knee arthritis is the most common form, affecting about 14 million people in the US and more than 5 million in the UK. Many will require knee surgery. In the UK more than 120,000 knee replacements are carried out every year. Continue reading...

Two men arrested in raid in which 12,000 doses of unlicensed weight-loss medicines recoveredA country estate near Northampton has become the centre of the largest-ever seizure of unlicensed weight-loss medicines in the UK.Two men, both aged 29, were arrested during a raid in which the Medicines and Healthcare products Regulatory Agency (MHRA) recovered about 12,000 doses of unlicensed weight-loss medicines. Continue reading...

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugsA new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday.The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss. Continue reading...

Experts say any short-term financial benefit will be outweighed by long-term health costs related to obesityFaced with high demand for GLP-1 drugs, some American cities and states that previously covered the cost of the weight-loss medication for low-income residents and public employees have now started to restrict or eliminate coverage.The pullback stems from the dramatic increase in public spending on drugs such as Ozempic and Wegovy in recent years. Continue reading...